Pulmonx (LUNG) Cost of Revenue (2019 - 2025)

Pulmonx (LUNG) has reported Cost of Revenue for 7 consecutive years, with $5.4 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Cost of Revenue rose 1.66% year-over-year to $5.4 million in Q3 2025; TTM through Sep 2025 was $24.5 million, a 19.45% increase from a year earlier, with the FY2024 full-year figure at $21.8 million, up 21.56% from the prior year.
• Cost of Revenue was $5.4 million for Q3 2025 at Pulmonx, down from $6.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.7 million in Q2 2025 and troughed at $500000.0 in Q4 2022.
• A 5-year average of $4.3 million and a median of $4.5 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue sank 85.54% in 2022 and soared 875.6% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $3.5 million in 2021, then sank by 85.54% to $500000.0 in 2022, then soared by 875.6% to $4.9 million in 2023, then increased by 26.59% to $6.2 million in 2024, then decreased by 11.74% to $5.4 million in 2025.
• The last three Cost of Revenue figures came in at $5.4 million (Q3 2025), $6.7 million (Q2 2025), and $6.2 million (Q1 2025), per Business Quant data.